| Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059] | Technology appraisal guidance | TBC |
| Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230] | Technology appraisal guidance | TBC |
| Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065 | Technology appraisal guidance | TBC |
| Abicipar pegol for treating wet age-related macular degeneration ID1533 | Technology appraisal guidance | TBC |
| Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378] | Technology appraisal guidance | TBC |
| Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232 | Technology appraisal guidance | TBC |
| Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] | Technology appraisal guidance | |
| Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy ID6354 | Technology appraisal guidance | TBC |
| Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339] | Technology appraisal guidance | |
| Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247] | Technology appraisal guidance | TBC |